Anticoagulants and thrombolytics showed potential new indications in individuals with cognitive impairment, necessitating validated shared decision-making.
What is the risk of new indications for anticoagulants and thrombolytics in people with cognitive impairment treated with anti-amyloid mAbs?
The study highlights the need to consider the risk of new indications for anticoagulants and thrombolytics when making shared decisions about anti-amyloid mAbs in patients with cognitive impairment.
Absolute Event Rate: 0% vs 0%
Our findings inform shared decision making about the tradeoffs of anti-amyloid mAbs but should be validated in populations with confirmed treatment eligibility.
Parks et al. (Mon,) reported a other. Anticoagulants and thrombolytics showed potential new indications in individuals with cognitive impairment, necessitating validated shared decision-making.